Product Description
Innovent Biologics is developing IBI-311, an intravenous injection drug candidate. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05480579?term=IBI-311&draw=2&rank=1)
Mechanisms of Action: PD-1 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innovent
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Innovent Biologics presented P1 Healthy Volunteers results on 2024-03-06 for IBI-311
- Clinical Outcomes Reported - Innovent Biologics presented P2 Thyroid Eye Disease results on 2024-03-06 for IBI-311
Highest Development Phases
Phase 3: Graves Disease|Graves Ophthalmopathy|Thyroid Eye Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06126783 |
CIBI311A301 | P3 |
Active, not recruiting |
Thyroid Eye Disease|Graves Disease|Graves Ophthalmopathy |
2026-05-30 |
44% |
2024-12-14 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20221581 |
CTR20221581 | P1 |
Completed |
Thyroid Eye Disease |
2023-01-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06525506 |
CIBI311A202 | P2 |
Completed |
Thyroid Eye Disease|Graves Ophthalmopathy|Graves Disease |
2025-01-09 |
12% |
2025-10-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT07113262 |
CIBI311A302 | P3 |
Not yet recruiting |
Thyroid Eye Disease|Graves Ophthalmopathy|Graves Disease |
2026-12-31 |
17% |
2025-08-13 |
Primary Endpoints|Treatments |
NCT05795621 |
CIBI311A201 | P3 |
Completed |
Graves Disease|Thyroid Eye Disease|Graves Ophthalmopathy |
2023-12-20 |
31% |
2024-02-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |